Analysts Issue Forecasts for Apyx Medical FY2026 Earnings

Apyx Medical Corporation (NASDAQ:APYX) – HC Wainwright increased their FY2026 earnings per share estimates for shares of Apyx Medical in a report issued on Friday, November 6th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.21) per share for the year, up from their previous forecast of ($0.25). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Apyx Medical’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Apyx Medical’s Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.04) EPS and FY2027 earnings at ($0.22) EPS.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. The firm had revenue of $14.03 million during the quarter, compared to the consensus estimate of $13.29 million.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, September 21st. Zacks Research raised Apyx Medical to a “hold” rating in a report on Tuesday, July 14th. Finally, Maxim Group began coverage on shares of Apyx Medical in a research report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $6.50.

Apyx Medical Stock Up 0.3%

Shares of APYX stock opened at $2.94 on Tuesday. The business’s 50 day moving average is $2.74 and its two-hundred day moving average is $3.58. Apyx Medical has a twelve month low of $2.25 and a twelve month high of $5.08. The company has a current ratio of 5.68, a quick ratio of 4.53 and a debt-to-equity ratio of 3.19.

Institutional Investors Weigh In On Apyx Medical

Hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new stake in Apyx Medical in the 2nd quarter valued at approximately $14,683,414. Royce & Associates LP increased its position in Apyx Medical by 7.0% during the 3rd quarter. Royce & Associates LP now owns 3,503,098 shares of the company’s stock worth $8,583,000 after purchasing an additional 229,034 shares during the period. AIGH Capital Management LLC acquired a new position in Apyx Medical during the 2nd quarter worth approximately $5,066,000. BlackRock Inc. purchased a new position in shares of Apyx Medical during the 2nd quarter worth approximately $2,519,000. Finally, Sei Investments Co. lifted its holdings in shares of Apyx Medical by 298.6% in the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after buying an additional 448,174 shares during the period. Institutional investors and hedge funds own 55.33% of the company’s stock.

More Apyx Medical News

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright increased its FY2026 EPS estimate to a loss of $0.21 from $0.25 and its FY2027 estimate to a loss of $0.22 from $0.25. It also raised quarterly forecasts, including Q4 2026 to a loss of $0.04 from $0.06 and Q1–Q3 2027 to losses of $0.06 each from $0.07. The firm reiterated its Buy rating and $7 target. MarketBeat APYX coverage
• Positive Sentiment: Maxim Group was reported to have maintained its Buy rating on APYX, offering additional analyst support, though this item is older than the latest estimate revisions. Maxim Group remains a Buy on Apyx Medical
• Neutral Sentiment: Apyx CEO Charles Goodwin presented at the 2026 UBS Global Healthcare Conference. The provided transcript listings do not identify a specific new announcement or outlook change. UBS conference transcript

Apyx Medical Company Profile

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.